文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症中的线粒体功能障碍:机制与治疗前景

Mitochondrial dysfunction in sepsis: mechanisms and therapeutic perspectives.
PubMed 文献 · Crit Care · 2024-09-03
一句话结论脓毒症中线粒体损伤通过活性氮/氧生成、线粒体自噬抑制、动力学改变和膜通透化驱动炎症与免疫失调,靶向线粒体的干预在临床前脓毒症模型中显示治疗效力。

本文为综述,聚焦脓毒症时线粒体功能障碍的机制及其对免疫失调的影响。脓毒症时活性氮/氧生成、线粒体自噬抑制、线粒体动力学改变和线粒体膜通透化等因素导致线粒体损伤;受损线粒体通过Toll样受体、NOD样受体和环鸟苷酸-腺苷酸合成酶介导的信号通路参与塑造炎症环境。作者重点介绍了在临床前脓毒症模型中显示治疗效力的靶向线粒体干预措施。

要点

  • 脓毒症时线粒体损伤由活性氮/氧生成、线粒体自噬抑制、线粒体动力学改变和线粒体膜通透化等多种机制驱动。
  • 受损线粒体通过Toll样受体、NOD样受体和环鸟苷酸-腺苷酸合成酶介导的信号通路主动参与塑造炎症环境。
  • 线粒体功能障碍在脓毒症进展和免疫失调中起核心作用,是潜在治疗靶点。
  • 靶向线粒体的干预措施在临床前脓毒症模型中已显示治疗效力。

研究设计与关键结果

  • 综述总结:脓毒症时活性氮/氧生成、线粒体自噬抑制、线粒体动力学改变和线粒体膜通透化等机制导致线粒体损伤。
  • 综述总结:受损线粒体通过Toll样受体、NOD样受体和环鸟苷酸-腺苷酸合成酶介导的信号通路参与塑造炎症环境。
  • 综述总结:靶向线粒体的干预措施在临床前脓毒症模型中已显示治疗效力。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis is a severe medical condition characterized by a systemic inflammatory response, often culminating in multiple organ dysfunction and high mortality rates. In recent years, there has been a growing recognition of the pivotal role played by mitochondrial damage in driving the progression of sepsis. Various factors contribute to mitochondrial impairment during sepsis, encompassing mechanisms such as reactive nitrogen/oxygen species generation, mitophagy inhibition, mitochondrial dynamics change, and mitochondrial membrane permeabilization. Damaged mitochondria actively participate in shaping the inflammatory milieu by triggering key signaling pathways, including those mediated by Toll-like receptors, NOD-like receptors, and cyclic GMP-AMP synthase. Consequently, there has been a surge of interest in developing therapeutic strategies targeting mitochondria to mitigate septic pathogenesis. This review aims to delve into the intricate mechanisms underpinning mitochondrial dysfunction during sepsis and its significant impact on immune dysregulation. Moreover, we spotlight promising mitochondria-targeted interventions that have demonstrated therapeutic efficacy in preclinical sepsis models.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Hu D, Sheeja Prabhakaran H, Zhang YY, et al. Mitochondrial dysfunction in sepsis: mechanisms and therapeutic perspectives. Crit Care. 2024. PMID: 39227925. doi:10.1186/s13054-024-05069-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。